

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – October 14, 2026 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Haymore, Chairman:

1. Call to Order

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Cassidy Blaiss –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Christen Ground –	participating in person
Dr. Bret Haymore –	participating in person
Dr. Bethany Holderread –	participating in person
Dr. Matt John –	participating in person
Dr. Craig Kupiec –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Jennifer Weakley –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:

https://oklahoma.zoom.us/webinar/register/WN_eBUt3qLzSkycOdDyUyZx5g

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 910 6408 1365

Passcode: 44589980

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.
- In lieu of speaking at the DUR Board meeting, written correspondence by members or providers may be submitted to DURPublicComment@okhca.org. Other written correspondence is not permitted.

Items to be presented by Dr. Haymore, Chairman:

2. Public Comment Forum

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Haymore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. September 9, 2026 DUR Board Meeting Minutes
- B. September 9, 2026 DUR Board Recommendations Memorandum
- C. Correspondence

Non-presentation items reviewed by Dr. Grimes, Dr. Haymore, Chairman:

4. Update on Medication Coverage Authorization Unit – See Appendix B

- A. Pharmacy Help Desk Activity for September 2025
- B. Medication Coverage Activity for September 2025

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

5. Fall Pipeline Update – See Appendix C

- A. Introduction
- B. Product Summaries
- C. Pipeline Table

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

6. Action Item – Vote to Prior Authorize Cetirizine Oral Solution Unit Dose Cups (UDCs) and Update the Approval Criteria for the Antihistamine Medications (Systemic) – See Appendix D

- A. Cost Comparison: Cetirizine Products
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

7. Action Item – Vote to Prior Authorize Epioxa HD/Epioxa (Riboflavin 5'-Phosphate Ophthalmic Solution) and Lumvoa (Veligrotug-vvze) and Update the Approval Criteria for the Various Ophthalmic Medications – See Appendix E

- A. Market News and Updates
- B. Lumvoa (Veligrotug-vvze) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

8. Action Item – Vote to Prior Authorize Beizray (Docetaxel), Beizray Kit (Docetaxel/Albumin), Docivyx (Docetaxel), Inluriyo (Imlunestrant), and Veppanu (Vepdegestrant) and Update the Approval Criteria for the Breast Cancer Medications – See Appendix F

- A. Market News and Updates
- B. Product Summaries
- C. Cost Comparisons
- D. College of Pharmacy Recommendations

Items to be presented by Dr. DeRemer, Dr. Haymore, Chairman:

9. Action Item – Annual Review of Constipation and Diarrhea Medications – See Appendix G

- A. Current Prior Authorization Criteria
- B. Utilization of Constipation and Diarrhea Medications
- C. Prior Authorization of Constipation and Diarrhea Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Constipation and Diarrhea Medications

Items to be presented by Dr. Grimes, Dr. Haymore, Chairman:

10. Action Item – Annual Review of Anticoagulants and Platelet Aggregation Inhibitors – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
- C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anticoagulants and Platelet Aggregation Inhibitors

Items to be presented by Dr. Sinko, Dr. Haymore, Chairman:

11. Annual Review of Myeloproliferative Neoplasm (MPN) Medications and 30-Day Notice to Prior Authorize Decnupaz (Pivekimab Sunirine-pvzy), Jakafi XR [Ruxolitinib Extended-Release (ER)], and Mimrylo (Rusfertide) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of MPN Medications
- C. Prior Authorization of MPN Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of MPN Medications

Items to be presented by Dr. Wilson, Dr. Haymore, Chairman:

12. Annual Review of Targeted Immunomodulator Agents and 30-Day Notice to Prior Authorize Icotyde (Icotrokinra), Immgolix (Golimumab-sldi), Immgolix Intri (Golimumab-sldi), Lisraya (Brepocitinib), and Zimrixby (Rituximab-cdxx) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Targeted Immunomodulator Agents
- C. Prior Authorization of Targeted Immunomodulator Agents
- D. Market News and Updates
- E. Product Summaries
- F. Cost Comparison: Rituximab Products
- G. College of Pharmacy Recommendations
- H. Utilization Details of Targeted Immunomodulator Agents

Items to be presented by Dr. Moss, Dr. Haymore, Chairman:

13. Annual Review of Fibromyalgia Medications and 30-Day Notice to Prior Authorize Tonmya [Cyclobenzaprine Sublingual (SL) Tablet] – See Appendix K

- A. Current Prior Authorization Criteria
- B. Utilization of Fibromyalgia Medications
- C. Prior Authorization of Fibromyalgia Medications
- D. Market News and Updates
- E. Tonmya (Cyclobenzaprine SL Tablet) Product Summary
- F. Cost Comparison
- G. College of Pharmacy Recommendations
- H. Utilization Details of Fibromyalgia Medications

Items to be presented by Dr. O'Halloran, Dr. Haymore, Chairman:

14. Annual Review of Anemia Medications and 30-Day Notice to Prior Authorize Aqvesme (Mitapivat) – See Appendix L

- A. Current Prior Authorization Criteria

- B. Utilization of Anemia Medications
- C. Prior Authorization of Anemia Medications
- D. Market News and Updates
- E. Aqvesme (Mitapivat) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anemia Medications

Non-presentation items reviewed by Dr. Grimes, Dr. Haymore, Chairman:

15. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix M

Items to be presented by Dr. Adams, Dr. Haymore, Chairman:

16. Future Business* (Upcoming Product and Class Reviews)

- A. Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications
- B. Atopic Dermatitis Medications
- C. Bone Density Regulators
- D. Brinsupri (Brensocatic)
- E. Gonadotropin-Releasing Hormone (GnRH) Medications (Non-Oncology)
- F. Multiple Myeloma Medications
- G. Ophthalmic Anti-Inflammatory Products
- H. Rhapsido (Remibrutinib)

*Future product and class reviews subject to change.

17. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.

NOTE: Oklahoma Medicaid transitioned from a fee-for-service (FFS) pharmacy benefit to a managed care pharmacy benefit for most members on April 1, 2024. At that time, the majority of SoonerCare members were transitioned to one of the three managed care SoonerSelect plans: Aetna, Humana, or Oklahoma Complete Health. SoonerSelect data has been provided to the College of Pharmacy and has been used in analyses throughout this DUR Board meeting packet. The data included in this DUR Board meeting packet combines FFS and managed care utilization data. The managed care utilization and prior authorization (PA) data reported in this packet is based solely on the data provided by the SoonerSelect plans.